• No notifications yet.
  • Edit Profile
  • Settings
  • Invite Friends
  • Sign Out
logo image
  • logo image
Registered User? Login

Access to the community is available for registered attendees only. If you have already registered - please join using the link below. 

To register for the event please follow the 'register now' button and summit your details. Please contact ftlive@ft.com with any questions.

Forgot Password?
Sign Up
loader image
New User? Sign Up

Access to the community is available for registered attendees only. If you have already registered - please join using the link below. 

To register for the event please follow the 'register now' button and summit your details. Please contact ftlive@ft.com with any questions.

Forgot Password?
Login
loader image

    Innovative Clinical Research Strategies

    FT DIGITAL DIALOGUES | ​Building resilience in pharma R&D by decentralising and digitising
    Wednesday 3 February 4:00pm GMT, 11am EST

    IN PARTNERSHIP WITH


    0
    DAYS
    0
    HOURS
    0
    MINUTES
    0
    SECONDS

    This FT Digital Dialogue on Innovative Clinical Research Strategies, organised in partnership with ICON plc, will discuss how to design and run more resilient trials in an uncertain world, where the need to decentralise is driving investment in new technology solutions and changing the pharma R&D landscape.

    SPEAKERS INCLUDE

    speaker image
    HK
    Hannah Kuchler
    US Pharma and Biotech Correspondent
    Financial Times
    speaker image
    JB
    José Baselga
    Executive Vice-President, Research & Development, Oncology
    AstraZeneca
    speaker image
    MI
    Melanie Ivarsson
    Chief Development Officer
    Moderna
    speaker image
    CK
    Christoph Koenen
    Executive Vice President Chief Medical Officer
    Otsuka
    speaker image
    NM
    Nuala Murphy
    President Clinical Research Services
    ICON

    KEY TALKING POINTS

    How is trial design evolving in terms of data collection, safety reporting, tracking and other processes? 


    What are some of the challenges around moving to remote study management and off-site monitoring? 


    What can be done to manage the risks and consequences of trials being suspended and re-started? 


    How could new approaches to clinical trial management affect access to patient populations and how can direct patient support services be improved?


    How can relationships with regulators, patients and other stakeholders evolve to accommodate new processes and solutions? 


    REGISTER FOR YOUR COMPLIMENTARY PASS

    FT Live events keep you connected and informed in an uncertain and constantly changing world. All access, digital passes include access to all the live sessions PLUS all sessions on demand for 30 days. Join the conversation.


    © Financial Times Live

    FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice

    LEGAL

    FAQs
    FT Live Website Terms of Use
    Slavery Statement & Policies
    Contact us
    FT Live Delegate Terms & Conditions
    Privacy policy
    Cookie policy


    SOCIAL

    Instagram
    Twitter
    LinkedIn
    YouTube
    Flickr